Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8...

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

DEMOGRAPHICS The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments...

Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter

Expected best selling drugs of 2025 based on revenues. Revenues of Ozempic, Dupixent, Mounjaro, Skyrizi, Eliquis, Biktarvy, Wegovy, Darzalex

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

1. Keytruda: Revolutionizing Cancer Care Keytruda (pembrolizumab), an immunotherapy drug by Merck, has transformed cancer treatment....

European Congress of Rheumatology, EULAR 2024 | News | Updates | iPharmaCenter

New Study Identifies Corticosteroid Management as Predictors of Organ Damage in Children with Lupus Childhood-onset systemic lupus...

Top pharma companies by revenues in 2023| Best Selling Drugs of 2023 |Top 20 pharma companies | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES 2023 Merck revenues exclude animal health revenues 1. JOHNSON AND JOHNSON Q1 REVENUES Johnson...

LATEST

View all

Top Drug Launches to Watch in 2025 | iPharmaCenter

Most Anticipated New Drug Launches of 2025 The pharmaceutical industry is set for another groundbreaking year in 2025, with several...

Novartis Strengthens Cardiovascular Portfolio with $3.1 Billion Anthos Therapeutics Acquisition | iPharmaCenter

Novartis has announced plans to acquire Anthos Therapeutics, a biopharmaceutical company specializing in cardiovascular treatments, for...

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

Top selling drugs of 2024 Sl No Brand Q1 Revenues 1 Keytruda $29.5 billion 2 Ozempic $16.7 billion 3 Dupixent $13.4 billion 4 Eliquis $...

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved Enhertu (trastuzumab...

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

CHMP gave a positive opinion for treating BMS' cell-therapy Breyanzi for relapsed or refractory follicular lymphoma Bristol Myers Squibb...

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

TOP PHARMACEUTICAL COMPANIES BY REVENUES IN 2024 Sl No Company Q1 Q2 Q3 Total Best selling products 1 JOHNSON AND JOHNSON $21.8 $43.8...

US FDA NEWS

EUROPE

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved Enhertu (trastuzumab...

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

The U.S. has granted approval for Enhertu as the first HER2-targeted treatment for patients with HER2-low or HER2-ultralow metastatic...

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

The U.S. Food and Drug Administration (FDA) has granted approval for tislelizumab, in combination with chemotherapy, as a first-line...

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

Eli Lilly has achieved a significant milestone by securing U.S. Food and Drug Administration (FDA) approval for Zepbound (tirzepatide) as...

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

The U.S. Food and Drug Administration (FDA) has approved Pfizer's Hympavzi (marstacimab) for the treatment of adults and adolescents aged...

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

The U.S. Food and Drug Administration (FDA) has approved Itovebi (inavolisib), a targeted therapy for adults with advanced or metastatic...

INDIA

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

CHMP gave a positive opinion for treating BMS' cell-therapy Breyanzi for relapsed or refractory follicular lymphoma Bristol Myers Squibb...

Rybrevant plus Lazcluze approved in Europe for EGFR-NSCLC; showed improvement over Tagrisso | iPharmaCenter

The European Commission has granted approval for the use of Rybrevant ( amivantamab) in combination with Lazcluze ( lazertinib) as a...

Novartis’ Kisqali Gains European Commission Approval for Broader Use in Early Breast Cancer Patients at High Risk of Recurrence | iPharmaCenter

The European Commission (EC) has approved Kisqali (ribociclib) in combination with aromatase inhibitors (AI) for the treatment of...

EMA Drug Approvals 2024 | CHMP Positive Opinion | October 2024 | iPharmaCenter

Alhemo recommended for European approval as first daily subcutaneous prophylactic treatment for haemophilia A or B patients with...

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

Merck's Keytruda (pembrolizumab), combined with Padcev (enfortumab vedotin), has received approval from the European Commission (EC) as a...

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

In a significant development, the European Commission has expanded the approval of Arexvy, GSK's respiratory syncytial virus (RSV)...

CHINA

Dr. Reddy’s Launches Toripalimab in India for Nasopharyngeal Carcinoma Treatment | iPharmaCenter

Dr. Reddy’s Laboratories has introduced Toripalimab in India, marking it as the first and only immuno-oncology therapy approved for...

Sanofi Secures Approval for Beyfortus in India to Shield Infants and Children from RSV | iPharmaCenter

Sanofi India announced the receipt of marketing authorization for Beyfortus (nirsevimab) from the Central Drugs Standard Control...

Indian Pharma News | 2024 | iPharmaCenter

May 21, 2024 Glenmark and BeiGene Collaborate to Market and Distribute Tislelizumab and Zanubrutinib in India Key Points: Tislelizumab:...

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

China’s National Medical Products Administration (NMPA) has approved Vyloytm (zolbetuximab) for use alongside fluoropyrimidine- and...

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

Nucala has become the first anti-interleukin-5 therapy approved in China for treating adults with chronic rhinosinusitis with nasal...

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

HUTCHMED and Innovent Biologics have announced that the China National Medical Products Administration (NMPA) has conditionally approved...

HEALTHCARE SYSTEMS

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

DEMOGRAPHICS The constitution of India ensures the "right to health" for every citizen. It is the responsibility of the state governments...

Brazil Healthcare System | How Brazil's healthcare work? Funding | How are drugs approved and reimbursed? | iPharmaCenter

Overview According to data from the Brazilian Federation of Hospitals (FBH) and the National Confederation of Health (CNSaúde), out of...

Vietnam Healthcare System | Drug regiatration and approvals | iPharmaCenter

The healthcare system in Vietnam is a dynamic combination of both public and private sectors, focusing on preventive medicine and...

Indonesia Healthcare System | Healthcare System | iPharmaCenter

OVERVIEW Indonesia has highest population after China, India, and USA, with a population of over 270 million people. The country's...

Saudi Arabia | Healthcare System | Drug approvals and pricing | iPharmaCenter

OVERVIEW Saudi Arabia accounts for two-thirds of the GCC population and is the largest healthcare market in the region. While it accounts...

MEXICO HEALTHCARE SYSTEM | DRUG PRICING AND REIMBURSEMENT IN MEXICO | NEWS | BLOGS | iPharmaCenter

OVERVIEW OF MEXICO HEALTHCARE SYSTEM Article 4 of Mexico's constitution guarantees the right to health for all citizens. Mexico has a...

HEALTHCARE SYSTEM IN CHINA

Overview of China healthcare system China achieved universal health coverage in 2011. The urban employed is covered via an...

Drug pricing and reimbursement in Germany | Health Technology Assessment in Germany

It is mandatory to have health insurance in Germany. Statutory Health Insurance covers 90% of the German population, and the rest, 10%,...

Why the cost of prescription drugs is high in the US?

The United States spends more on prescription drugs compared to other developed nations. On average, the United States spends as much as...

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

Expected best selling drugs of 2025 | Top pharmaceuticals by revenues | iPharmaCenter

Expected | Best selling drugs of 2024 | Top selling drugs of 2024 | iPharmaCenter

European Congress of Rheumatology, EULAR 2024 | News | Updates | iPharmaCenter

Top pharma companies by revenues in 2023| Best Selling Drugs of 2023 |Top 20 pharma companies | iPharmaCenter

LATEST

Top Drug Launches to Watch in 2025 | iPharmaCenter

Novartis Strengthens Cardiovascular Portfolio with $3.1 Billion Anthos Therapeutics Acquisition | iPharmaCenter

Top selling drugs of 2024 | Best selling drugs of 2024 | iPharmaCenter

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

Top pharmaceutical companies by revenues in 2024 | Biggest Pharma of 2024 | Top Pharma profits | iPharmaCenter

Subscribe to Our Newsletter

US FDA NEWS

EUROPE

AstraZeneca's ADC Enhertu is now approved in US for HR-positive, HER2-low or ultra low breast cancer | iPharmaCenter

FDA Grants Approval for Enhertu in HER2-Positive Breast Cancer Following Endocrine Therapy | iPharmaCenter

BeiGene's PD-L1 inhibitor Tevimbra approved in the US for advanced gastric or gastroesophageal junction (G/GEJ) cancers | iPharmaCenter

Lilly Secures FDA Approval for Zepbound in Obstructive Sleep Apnea, Outpacing Novo Nordisk | Pharma Breaking News | iPharmaCenter

US FDA Approved Pfizer's Hympavzi for hemophilia A or B, who do not have inhibitors | FDA Approved | iPharmaCenter

Roche aims to strengthen its breast cancer portfolio with the approval of Itovebi | FDA Approval | iPharmaCenter

INDIA

European Drug Approvals | CHMP Positive Opinions | January 2025 | iPharmaCenter

Rybrevant plus Lazcluze approved in Europe for EGFR-NSCLC; showed improvement over Tagrisso | iPharmaCenter

Novartis’ Kisqali Gains European Commission Approval for Broader Use in Early Breast Cancer Patients at High Risk of Recurrence | iPharmaCenter

EMA Drug Approvals 2024 | CHMP Positive Opinion | October 2024 | iPharmaCenter

European Commission Greenlights Keytruda and Padcev Combo as First-Line Treatment for Advanced Urothelial Carcinoma | iPharmaCenter

European Commission Expands Approval for GSK's Arexvy, the First RSV Vaccine for Adults Aged 50-59 at Increased Risk | iPharmaCenter

CHINA

Dr. Reddy’s Launches Toripalimab in India for Nasopharyngeal Carcinoma Treatment | iPharmaCenter

Sanofi Secures Approval for Beyfortus in India to Shield Infants and Children from RSV | iPharmaCenter

Indian Pharma News | 2024 | iPharmaCenter

Vyloytm (zolbetuximab) Gains Approval in China for First-Line Treatment of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma | iPharmaCenter

China Approves GSK’s Nucala for Chronic Rhinosinusitis with Nasal Polyps in Adults | iPharmaCenter

HUTCHMED and Innovent Announce Conditional Approval of Fruquintinib and Sintilimab Combination for Advanced Endometrial Cancer in China | iPharmaCenter

HEALTHCARE SYSTEMS

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

Brazil Healthcare System | How Brazil's healthcare work? Funding | How are drugs approved and reimbursed? | iPharmaCenter

Vietnam Healthcare System | Drug regiatration and approvals | iPharmaCenter

Indonesia Healthcare System | Healthcare System | iPharmaCenter

Saudi Arabia | Healthcare System | Drug approvals and pricing | iPharmaCenter

MEXICO HEALTHCARE SYSTEM | DRUG PRICING AND REIMBURSEMENT IN MEXICO | NEWS | BLOGS | iPharmaCenter

HEALTHCARE SYSTEM IN CHINA

Drug pricing and reimbursement in Germany | Health Technology Assessment in Germany

Why the cost of prescription drugs is high in the US?